CY1123482T1 - Παραγωγα βενζιμιδαζολιου ως αναστολεις nav 1.7 (διαυλος νατριου, περιορισμενης ηλεκτρικης τασης, τυπου ix, αλφα υπομοναδα (scn9a)) για θεραπεια πονου, δυσουριας και σκληρυνσης κατα πλακας - Google Patents

Παραγωγα βενζιμιδαζολιου ως αναστολεις nav 1.7 (διαυλος νατριου, περιορισμενης ηλεκτρικης τασης, τυπου ix, αλφα υπομοναδα (scn9a)) για θεραπεια πονου, δυσουριας και σκληρυνσης κατα πλακας

Info

Publication number
CY1123482T1
CY1123482T1 CY20201100973T CY201100973T CY1123482T1 CY 1123482 T1 CY1123482 T1 CY 1123482T1 CY 20201100973 T CY20201100973 T CY 20201100973T CY 201100973 T CY201100973 T CY 201100973T CY 1123482 T1 CY1123482 T1 CY 1123482T1
Authority
CY
Cyprus
Prior art keywords
pain
treatment
nav
nodium
scn9a
Prior art date
Application number
CY20201100973T
Other languages
English (en)
Inventor
Masafumi KOMIYA
Kohei Iwamoto
Toshio Kanai
Shingo MIZUSHIMA
Keiji Adachi
Kuniko URASHIMA
Original Assignee
Sumitomo Dainippon Pharma Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co., Ltd. filed Critical Sumitomo Dainippon Pharma Co., Ltd.
Publication of CY1123482T1 publication Critical patent/CY1123482T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει ένα φάρμακο για τη θεραπεία ασθένειας που περιλαμβάνει Nav 1.7 όπως νευροπαθητικού πόνου, αλγαισθητικού πόνου, φλεγμονώδους πόνου, μικρής ίνας νευροπάθεια, ερυθρομελαλγία, παροξυσμικής ακραίου πόνου διαταραχής, δυσουρίας και σκλήρυνσης κατά πλάκας, που περιλαμβάνει ένωση του τύπου (Ι) ή φαρμακευτικώς αποδεκτό άλας αυτής, όπου R1a, R1b, R1c και R1d είναι υδρογόνο, αλογόνο, κύανο, C1-4 αλκύλ, C1-4 αλκόξυ, ή οι παρόμοιες, υπό την προϋπόθεση ότι τουλάχιστον μία των R1a, R1b, R1c και R1d είναι C6-10 αρύλ, C6-10 αρυλόξυ, ή οι παρόμοιες, R2 και R3 είναι υδρογόνο, C1-6 αλκύλ, C3-10 κυκλοαλκύλ, ή οι παρόμοιες, R4 είναι υδρογόνο, C1-6 αλκύλ, C3-7 κυκλοαλκύλ, ή οι παρόμοιες, m είναι 1, 2 ή 3, L είναι CR7R8, και R7 και R8 είναι υδρογόνο, υδροξύλ, C1-4 αλκύλ, C1-4 αλκόξυ, ή οι παρόμοιες.
CY20201100973T 2015-09-11 2020-10-14 Παραγωγα βενζιμιδαζολιου ως αναστολεις nav 1.7 (διαυλος νατριου, περιορισμενης ηλεκτρικης τασης, τυπου ix, αλφα υπομοναδα (scn9a)) για θεραπεια πονου, δυσουριας και σκληρυνσης κατα πλακας CY1123482T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015179663 2015-09-11
PCT/JP2016/076645 WO2017043636A1 (ja) 2015-09-11 2016-09-09 新規ベンズイミダゾール化合物およびその医薬用途

Publications (1)

Publication Number Publication Date
CY1123482T1 true CY1123482T1 (el) 2022-03-24

Family

ID=58239905

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100973T CY1123482T1 (el) 2015-09-11 2020-10-14 Παραγωγα βενζιμιδαζολιου ως αναστολεις nav 1.7 (διαυλος νατριου, περιορισμενης ηλεκτρικης τασης, τυπου ix, αλφα υπομοναδα (scn9a)) για θεραπεια πονου, δυσουριας και σκληρυνσης κατα πλακας

Country Status (18)

Country Link
US (2) US10407395B2 (el)
EP (1) EP3348547B1 (el)
JP (1) JP6768674B2 (el)
KR (1) KR102654710B1 (el)
CN (1) CN107922350B (el)
AU (1) AU2016319597B2 (el)
CA (1) CA2989992A1 (el)
CY (1) CY1123482T1 (el)
DK (1) DK3348547T3 (el)
ES (1) ES2818529T3 (el)
HK (1) HK1251225A1 (el)
HU (1) HUE052395T2 (el)
LT (1) LT3348547T (el)
PL (1) PL3348547T3 (el)
PT (1) PT3348547T (el)
SI (1) SI3348547T1 (el)
TW (1) TWI710554B (el)
WO (1) WO2017043636A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2818529T3 (es) * 2015-09-11 2021-04-13 Sumitomo Dainippon Pharma Co Ltd Derivados de bencimidazol como inhibidores Nav 1.7 (subunidad alfa del canal de sodio, dependiente del voltaje, tipo IX (SCN9A)) para tratar el dolor, la disuria y la esclerosis múltiple
US11242332B2 (en) 2017-03-15 2022-02-08 Sumitomo Dainippon Pharma Co., Ltd. Method for producing benzimidazole derivative
JP7165501B2 (ja) * 2017-03-15 2022-11-04 住友ファーマ株式会社 新規ベンズイミダゾール化合物からなる医薬
JP7090069B2 (ja) * 2017-03-15 2022-06-23 住友ファーマ株式会社 重水素化ベンズイミダゾール化合物およびその医薬用途
KR102183676B1 (ko) 2018-04-17 2020-11-27 주식회사 엘지화학 타원 편광판 및 유기발광장치
WO2023160004A1 (zh) * 2022-02-25 2023-08-31 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003091258A1 (en) 2002-04-26 2003-11-06 Pfizer Products Inc. N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
CN1902181A (zh) * 2003-10-28 2007-01-24 沃泰克斯药物股份有限公司 可用作离子通道调控剂的苯并咪唑
EP1753730A1 (en) * 2004-06-04 2007-02-21 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2011158108A2 (en) * 2010-06-16 2011-12-22 Purdue Pharma L.P. Aryl substituted indoles and the use thereof
WO2012057262A1 (ja) 2010-10-28 2012-05-03 日本新薬株式会社 ピリジン誘導体及び医薬
WO2012116440A1 (en) * 2011-03-03 2012-09-07 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
WO2012172043A1 (en) * 2011-06-15 2012-12-20 Laboratoire Biodim Purine derivatives and their use as pharmaceuticals for prevention or treatment of bacterial infections
EP2809655B1 (en) * 2012-02-03 2015-08-12 Pfizer Inc Benziimidazole and imidazopyridine derivatives as sodium channel modulators
JPWO2014054635A1 (ja) 2012-10-02 2016-08-25 大日本住友製薬株式会社 イミダゾール誘導体
JP2016516710A (ja) * 2013-03-13 2016-06-09 アッヴィ・インコーポレイテッド ピリジン系ｃｄｋ９キナーゼ阻害薬
JP2016169161A (ja) * 2013-07-19 2016-09-23 大日本住友製薬株式会社 新規イミダゾピリジン化合物
US9828348B2 (en) * 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
MA40957A (fr) * 2014-10-09 2017-09-19 Biomarin Pharm Inc Inhibiteurs de biosynthèse d'héparane sulfate pour traiter des maladies
JP2018052817A (ja) * 2015-01-21 2018-04-05 大日本住友製薬株式会社 新規ベンズイミダゾール誘導体およびその医薬用途
MA41803A (fr) 2015-03-24 2018-01-30 Almirall Sa Dérivés amino-indazoles utilisés comme inhibiteurs des canaux sodiques
BR112017022860A2 (pt) 2015-04-21 2018-07-17 Gtx Inc ligantes de decompostos receptores de andrógeno seletivos (sard) e métodos de utilização dos mesmos
ES2818529T3 (es) * 2015-09-11 2021-04-13 Sumitomo Dainippon Pharma Co Ltd Derivados de bencimidazol como inhibidores Nav 1.7 (subunidad alfa del canal de sodio, dependiente del voltaje, tipo IX (SCN9A)) para tratar el dolor, la disuria y la esclerosis múltiple

Also Published As

Publication number Publication date
CN107922350B (zh) 2022-04-19
CN107922350A (zh) 2018-04-17
EP3348547B1 (en) 2020-07-22
TWI710554B (zh) 2020-11-21
RU2018105683A3 (el) 2019-12-26
AU2016319597B2 (en) 2020-12-24
US20170107211A1 (en) 2017-04-20
PT3348547T (pt) 2020-10-12
WO2017043636A1 (ja) 2017-03-16
EP3348547A1 (en) 2018-07-18
US20180170881A1 (en) 2018-06-21
JPWO2017043636A1 (ja) 2018-06-28
KR102654710B1 (ko) 2024-04-03
HK1251225A1 (zh) 2019-01-25
LT3348547T (lt) 2020-11-10
PL3348547T3 (pl) 2020-12-14
AU2016319597A1 (en) 2018-02-01
RU2018105683A (ru) 2019-10-14
HUE052395T2 (hu) 2021-04-28
US9688670B2 (en) 2017-06-27
SI3348547T1 (sl) 2020-10-30
ES2818529T3 (es) 2021-04-13
TW201713629A (zh) 2017-04-16
CA2989992A1 (en) 2017-03-16
US10407395B2 (en) 2019-09-10
JP6768674B2 (ja) 2020-10-14
KR20180044317A (ko) 2018-05-02
DK3348547T3 (da) 2020-09-14
EP3348547A4 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
CY1123482T1 (el) Παραγωγα βενζιμιδαζολιου ως αναστολεις nav 1.7 (διαυλος νατριου, περιορισμενης ηλεκτρικης τασης, τυπου ix, αλφα υπομοναδα (scn9a)) για θεραπεια πονου, δυσουριας και σκληρυνσης κατα πλακας
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1125214T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1119585T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CO2022008091A2 (es) Inhibidores de kras g12c
CY1124257T1 (el) N-[4-ΦΘOPO-5-[[(2S,4S)-2-MEΘYΛO-4-[(5-MEΘYΛO-1,2,4-ΟΞAΔIAZOΛ-3-YΛO)MEΘOΞY]-l-ΠΙΠΕΡΙΔΥΛΟ]ΜΕΘΥΛΟ]ΘΕΙΑΖΟΛ-2-ΥΛΟ]ΑΚΕΤΑΜΙΔΙΟ ΩΣ ΑΝΑΣΤΟΛΕΑΣ OGA
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
AR122783A2 (es) Inhibidores de kras g12c y métodos para su uso
CY1124622T1 (el) Μεθοδοι θεραπειας του καρκινου με τη χρηση 3-(4-((4-(μορφολινομεθυλ)βενζυλ)οξυ)-1-οξοϊσοϊνδολιν-2-υλ)πιπεριδινο- 2,6-διονης
CY1122340T1 (el) Αντιπολλαπλασιαστικες ενωσεις και μεθοδοι χρησης αυτων
CY1122919T1 (el) Διεγερτες sgc
CY1118128T1 (el) Αρυλ διϋδροπυριδινονες και πιπεριδiνονες ως αναστολεις του mgat2
CY1121677T1 (el) Ενωσεις διμεθυλοβενζοϊκου οξεος
CY1123487T1 (el) Διαμορφωτες του ρυθμιστη αγωγιμοτητας διαμεμβρανης κυστικης ινωσης
CY1124652T1 (el) Παραγωγα 1η-ινδαζολο-3-καρβοξαμιδιου και σχετικες ενωσεις ως αναστολεις παραγοντα d για τη θεραπεια νοσων που χαρακτηριζονται απο μη φυσιολογικη δραστηριοτητα συστηματος συμπληρωματος, οπως π.χ. ανοσολογικες διαταραχες
CY1119727T1 (el) Ενωσεις και συνθεσεις για τη θεραπεια παρασιτικων νοσων
CY1117431T1 (el) 2-(2,4,5-υποκατεστημενα-ανιλινο) παραγωγα πυριμιδινης ως ρυθμιστες egfr χρησιμα για τη θεραπευτικη αντιμετωπιση του καρκινου
CY1123930T1 (el) Συνδυασμοι fgfr και cmet αναστολεων για τη θεραπεια του καρκινου
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CY1119398T1 (el) Θεραπευτικα πολυμερικα νανοσωματιδια και μεθοδοι παρασκευης και χρησης αυτων
CY1116628T1 (el) Ενωσεις σπειρο-οξινδολιου και χρηση αυτων ως θεραπευτικοι παραγοντες
MX2021015708A (es) Compuestos para el tratamiento de enfermedades de pd-l1.
AR067646A1 (es) Ariloxazoles sustituidos y su uso
CY1119642T1 (el) Csf-1r αναστολεις για την θεραπεια ογκων του εγκεφαλου